2021 Q1 Results
2021 - 2023 Strategy and Outlook Update
Milano, 6 May 2021
Agenda
- Company overview and strategy
- First quarter 2021 results
- Drivers of organic growth - key assumptions
- Further growth opportunities through BD and R&D
- Financial projections
2
Recordati Today - Summary Overview
Business Overview | Recordati Snapshot - FY 2020 |
International specialty pharmaceutical group:
- Well diversified footprint
- Strong vertical integration
Specialty and Primary Care Division (78% sales):
- Prescription products: well-established, branded portfolio of prescription drugs focused on core therapeutic areas across cardiovascular, urology, gastrointestinal and central nervous system (57% sales)
- OTC: marketing of branded OTC products primarily in Europe (18% sales)
- Chemicals: production of active pharmaceutical ingredients ("API") sold to third party pharmaceutical companies (3% sales)
- Direct operations in all European markets, in Russia and C.I.S., Turkey and North Africa
€1.45bn | €569m | €355m | ~150 | > 4,300 |
Net | ||||
EBITDA(1) | Net Income | Markets | Employees | |
Revenue | ||||
Specialty & Primary Care | Rare Disease | |||
• | €1,129.5m Revenue | • | €319.4m Revenue | |
• | EBITDA margin 37.3% | • | EBITDA margin 46.4% | |
• | EBIT margin 30.9% | • | EBIT margin 37.5% |
Rare Diseases Division (22% sales):
- Treatments for rare diseases, particularly metabolic deficiencies and rare endocrine conditions of a genetic origin
- Active product development pipeline
- Worldwide business (US, EMEA and RoW)
8 manufacturing facilities (of which 2 API production sites) and a specialised packaging and distribution facility dedicated to rare diseases
- Pharma Production in Italy, Turkey, France, Tunisia, Spain, and Czech Republic
- API Manufacturing in Ireland and Italy
By Geography (2) | By Therapeutic Area (2) | ||||
Other | |||||
North | international | Cardiovascular | |||
sales 14.4% | 31.3% | ||||
Africa | Italy 19.0% | Gastro & metabolism | |||
2.9% | |||||
Other W. | 23.2% | ||||
Europe 6.5% | France | ||||
CEE 6.5% | 10.3% | ||||
Portugal | Germany | Other 13.3% | Genito-urinary | ||
11.2% | |||||
3.1% | 9.7% | ||||
Central nervous | |||||
Turkey | |||||
Russia, other CIS | system 4.2% | Respiratory 6.2% | |||
5.7% | |||||
Spain | U.S.A. | and Ukraine | Endo * | Musculoskeletal | |
6.0% | 7.2% | 6.2% | |||
8.7% | 4.4% | ||||
(1) Net income before income taxes, financial income and expenses, depreciation, amortization and write-downs of property, plant and equipment, intangible assets and goodwill,
3 and non-recurring items. (2) Breakdown based on pharmaceutical sales; * Endo 2020 includes direct Recordati sales only (net margin transfer from Novartis excluded) Based on FY 2020 reported financials
We have a proven and sustainable Business Model…
Well Diversified Revenue Base
Pursue Accretive and Growth Deals
- Strong M&A track record of product and corporate acquisitions as well as licensing to complement portfolio
- Disciplined approach, with focus on long term value creation (mix of growth and accretive deals)
Minimize development risk
- Selective R&D investments with majority of net revenue coming from mature products and products sourced externally via licensing and BD
- Very broad portfolio and diversified footprint minimizes exposure to single product/ market combination
- Limited exposure to single reimbursement systems
Focus on Volume-Led Growth
• Organic growth primarily fueled by volume-
driven growth rather than price
• Good exposure to markets with positive growth outlook (Turkey, Russia, North Africa)
Carefully manage LOEs
• Proven successful strategy of stabilising key products post LOE, through active promotion
• No major LOE exposure over the next 5 years
Control Supply | |
• Fully vertical integrated platform from API | |
to sale for key products, driving margin and | |
protecting the supply chain | |
4 | • c.60% of volumes manufactured by |
Recordati plants | |
…that has delivered consistent growth and margin improvement
Sales and profitability driven by organic growth and successful BD
(million Euro)
CAGR (10-20): +7% | 1,482 | 1,449 | ||||||
1,352 | ||||||||
1,288 | ||||||||
1,154 | ||||||||
1,048 | ||||||||
942 | 987 | 39% | ||||||
37% | 37% | |||||||
828 | 35% | |||||||
762 | ||||||||
728 | 30% | 32% | ||||||
28% | ||||||||
25% | 25% | 23% | 24% | |||||
2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | |
Net revenue | EBITDA % | ||||||||||
5
Questo è un estratto del contenuto originale. Per continuare a leggere, accedi al documento originale.
Attachments
- Original document
- Permalink
Disclaimer
Recordati S.p.A. published this content on 06 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 May 2021 12:26:04 UTC.